Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

29.19 -0.75 (-2.51%)

Delayed Quote Updated: 12:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

34 35 Next >

Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity ↗

July 05, 2024

Via Benzinga

Forget Eli Lilly: 3 Biotech Stocks to Buy Instead ↗

July 04, 2024

Eli Lilly is a good stock to buy, but these should be even better.

Via The Motley Fool

S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday? ↗

July 03, 2024

The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June’s sharply lower-than-expected services sector...

Via Benzinga

Topics Economy Stocks

3 Biotech Moonshots With Imminent Catalyst Potential ↗

July 03, 2024

Biotech has been one of the most explosive sectors. Better, further upside is likely, thanks to some of the top biotech stocks with catalysts.

Via InvestorPlace

Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today ↗

July 01, 2024

Via Benzinga

Viking Therapeutics Unusual Options Activity For June 25 ↗

June 25, 2024

Via Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth $600 Today ↗

June 18, 2024

Via Benzinga

Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?

July 03, 2024

Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases

Via MarketBeat

Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes

July 02, 2024

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy

Via MarketBeat

Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market

July 01, 2024

Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.

Via MarketBeat

Viking Therapeutics Unusual Options Activity For June 12 ↗

June 12, 2024

Via Benzinga

Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year? ↗

July 01, 2024

It's a tough act to follow.

Via The Motley Fool

3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics ↗

June 30, 2024

While their share prices have traveled different paths recently, the similarity between the two companies is striking.

Via The Motley Fool

The 3 Smartest Biotech Stocks to Buy With $5K Right Now ↗

June 28, 2024

With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.

Via InvestorPlace

The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains ↗

June 28, 2024

Consider buying shares in these pharma companies, each of which is a leader in the weight loss drug sector.

Via InvestorPlace

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗

June 28, 2024

These healthcare stocks have clear paths to growth over the next few years.

Via The Motley Fool

Better Growth Stock: Archer Aviation or Viking Therapeutics? ↗

June 26, 2024

Which one of these potential disruptors is the better buy?

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

June 25, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

June 24, 2024

Via Benzinga

The Best Biotech Stock to Invest $1,000 in Right Now ↗

June 18, 2024

This stock may not be a slam dunk, but it's looking very promising.

Via The Motley Fool

3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street ↗

June 17, 2024

These high-flying stocks could have more room to run if analysts are right.

Via The Motley Fool

2 Growth Stocks Wall Street Analysts Think Can Soar by at Least 80% ↗

June 15, 2024

There's a lot of hope for these stocks, but there's also a fair amount of risk.

Via The Motley Fool

Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It ↗

June 15, 2024

Just because a stock has amazing growth prospects doesn't mean you should ignore its valuation.

Via The Motley Fool

Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug ↗

June 14, 2024

Novo Nordisk's competition in the obesity drug market is heating up.

Via The Motley Fool

3 Stocks Under $10 Set to Quadruple by 2025: June Edition ↗

June 13, 2024

Low-priced stocks under $10 can be explosively awarding if you spot the right one at the right time with the right catalyst.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

June 13, 2024

Via Benzinga

3 Stocks to Buy if You Want to Turn Your $1,000 into $10,000 Within 2 Years ↗

June 13, 2024

One of the best ways to spot winning stocks to buy is by spotting hot trends, such as artificial intelligence and obesity.

Via InvestorPlace

Topics Artificial Intelligence

3 Stocks Quietly Preparing for a 10X Surge: June Edition ↗

June 12, 2024

There are plenty of 10x stocks with the potential to surge 10x over. We’ve already seen in happen with Apple, Netflix, Microsoft and Nvidia.

Via InvestorPlace

Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet ↗

June 10, 2024

The company is focusing on obesity treatment after its glaucoma drug failed.

Via Investor's Business Daily

Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals ↗

June 10, 2024

Success isn't guaranteed, but both companies could become big winners.

Via The Motley Fool

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.